Abstract:Background: Osteoporosis, a systemic metabolic bone disease, is often caused by the disruption of dynamic equilibrium between osteoclasts and osteoblasts. Overactive bone resorption, in which osteoclasts play a major role, is one of the most common and major causes of osteoporosis. Less costly and more effective drug treatments for this disease are needed. Based on the combination of molecular docking techniques and in vitro cell assays, this study aimed to explore the mechanism by which Isoliensinine (ILS) protects the bone loss by inhibiting osteoclast differentiation. Methods: A virtual docking model based on molecular docking technology was used to investigate the interactions between ILS and the Receptor Activator of Nuclear Kappa-B (RANK)/Receptor Activator of Nuclear Kappa-B Ligand (RANKL).In this study, we determined the effective dose of action of ILS to inhibit osteoclast differentiation in vitro and, using bone resorption experiments, RT-CPR and Western Blot investigated the effects of ILS on bone resorption function and normal expression of osteoclast-associated genes and proteins, and validated potential mechanistic pathways. In vivo experiments revealed that ILS could inhibit bone loss through Micro-CT results. Finally, the molecular interaction between ILS and RANK/RANKL was investigated using biomolecular interaction experiments to verify the correctness and accuracy of the computational results. Results: ILS binds to RANK and RANKL proteins, respectively, through virtual molecular docking. The Surface Plasmon Resonance (SPR) experiment results revealed that phosphorylated JNK, ERK, P38, and P65 expression was significantly downregulated when ILS were targeted to inhibit RANKL/RANK binding. At the same time, the expression of IKB-a was significantly increased under the stimulation of ILS, which rescued the degradation of IKB-a. ILS can significantly inhibit the levels of Reactive Oxygen Species (ROS) and Ca2 + concentration in vitro. Finally, the results of Micro-CT showed that ILS can significantly inhibit bone loss in vivo, indicating that ILS has a potential role in the treatment of osteoporosis. Conclusion: ILS inhibits osteoclast differentiation and bone loss by preventing the normal binding of RANKL/RANK, affecting downstream signaling pathways, including MAPK.NF-KB, ROS, Ca2+, genes, and proteins.

IL-3 inhibits rat osteoclast differentiation induced by TNF-α and other pro-osteoclastogenic cytokines

Isoalantolactone Inhibits RANKL-induced Osteoclast Formation Via Multiple Signaling Pathways

Corilagin Suppresses RANKL‐induced Osteoclastogenesis and Inhibits Oestrogen Deficiency‐induced Bone Loss Via the NF‐κB and PI3K/AKT Signalling Pathways

Interleukin-3 Plays Dual Roles in Osteoclastogenesis by Promoting the Development of Osteoclast Progenitors but Inhibiting the Osteoclastogenic Process

A Novel Inhibitor INF 39 Promotes Osteogenesis Via Blocking the NLRP3/IL-1β Axis

The emerging role of IMD 0354 on bone homeostasis by suppressing osteoclastogenesis and bone resorption, but without affecting bone formation

Molecular Basis of Requirement of Receptor Activator of Nuclear Factor Κb Signaling for Interleukin 1-Mediated Osteoclastogenesis.

STAT3 controls osteoclast differentiation and bone homeostasis by regulating NFATc1 transcription

NLRC3 attenuates osteoclastogenesis by limiting TNFα+ Th17 cell response in osteoporosis

Tectorigenin inhibits RANKL-induced osteoclastogenesis via suppression of NF-κB signalling and decreases bone loss in ovariectomized C57BL/6.

RhoA Promotes Osteoclastogenesis and Regulates Bone Remodeling Through Mtor-Nfatc1 Signaling.

Interleukin‐4 Inhibits RANKL‐induced NFATc1 Expression Via STAT6: A Novel Mechanism Mediating Its Blockade of Osteoclastogenesis

RBP-J–Regulated Mir-182 Promotes TNF-α–Induced Osteoclastogenesis

Interleukin-35 Inhibits TNF-α-Induced Osteoclastogenesis and Promotes Apoptosis Via Shifting the Activation from TNF Receptor-Associated Death Domain (TRADD)–TRAF2 to TRADD–Fas-Associated Death Domain by JAK1/STAT1

Isoliensinine suppresses bone loss by targeted inhibition of RANKL-RANK binding

TNF-induced Osteoclastogenesis and Inflammatory Bone Resorption Are Inhibited by Transcription Factor RBP-J.

TNF is a homoeostatic regulator of distinct epigenetically primed human osteoclast precursors

The Effect of Interleukin-1β, Tumour Necrosis Factor a and Particle Phagocytosis on Monocyte-Osteoclast Differentiation

Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats.

Knockdown of Tcirg1 inhibits large-osteoclast generation by down-regulating NFATc1 and IP3R2 expression

Tumor Necrosis Factor α Stimulates Osteoclast Differentiation by a Mechanism Independent of the Odf/Rankl–Rank Interaction